IL6 and neoplasm: One study designed HA-based combination adjuvant systems by combining HA with immunostimulatory compounds (HA; Mw = 500–1300 kDa), showing anti-tumor therapeutic effects by prevention of tumor proliferation and a significant increase in the cytokine secretion of IL-6 and TNF-α [129].